Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Afuresertib hydrochloride 是一个口服有效的,ATP 竞争性的选择性泛Akt 抑制剂,作用于Akt1、Akt2和Akt3,Ki 值分别为 0.08、2和 2.6 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 470 | 现货 | ||
2 mg | ¥ 671 | 现货 | ||
5 mg | ¥ 925 | 现货 | ||
10 mg | ¥ 1,389 | 现货 | ||
25 mg | ¥ 2,561 | 现货 | ||
50 mg | ¥ 3,927 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 943 | 现货 |
产品描述 | Afuresertib hydrochloride is an inhibitor of Akt kinase (Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively) |
靶点活性 | Akt3:2.6 nM(Ki), Akt2:2 nM(Ki), Akt1:0.08 nM(Ki) |
体外活性 | Afuresertib-induced p21 expression promotes G1 phase arrest by inducing FOXO activity.?Furthermore, afuresertib significantly enhanced cisplatin-induced cytotoxicity.Afuresertib modulated the expression E2F1 and MYC, which are associated with fibroblast core serum response.?Suggest that afuresertib is a useful anticancer drug for treating patients with MPM[1]. |
细胞实验 | Cell confluence proliferation assay was performed using Incucyte ZOOM Live‐Cell Imaging System.?Briefly, ACC‐MESO‐4 and MSTO‐211H cells were seeded in 12‐well plates (cell density, 1 × 104 cells/well) and were incubated for 24 h at 37°C.?Then, the cells were incubated with 0, 2, 5, or 10 μmol/L afuresertib.?During treatment, cell growth was monitored by recording phase images using the IncuCyte ZOOM Live‐Cell Imaging System (magnification, ×100)[1]. |
分子量 | 463.8 |
分子式 | C18H18Cl3FN4OS |
CAS No. | 1047645-82-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (215.62 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1561 mL | 10.7805 mL | 21.561 mL | 53.9025 mL |
5 mM | 0.4312 mL | 2.1561 mL | 4.3122 mL | 10.7805 mL | |
10 mM | 0.2156 mL | 1.0781 mL | 2.1561 mL | 5.3903 mL | |
20 mM | 0.1078 mL | 0.539 mL | 1.0781 mL | 2.6951 mL | |
50 mM | 0.0431 mL | 0.2156 mL | 0.4312 mL | 1.0781 mL | |
100 mM | 0.0216 mL | 0.1078 mL | 0.2156 mL | 0.539 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Afuresertib hydrochloride 1047645-82-8 Cell Cycle/Checkpoint Chromatin/Epigenetic Cytoskeletal Signaling PI3K/Akt/mTOR signaling Stem Cells ROCK Akt PKC Afuresertib Afuresertib Hydrochloride Protein kinase C PKB Rho-kinase GSK2110183 ROK Rho-associated protein kinase Inhibitor GSK-2110183 inhibit Protein kinase B Rho-associated kinase GSK 2110183 inhibitor